Literature DB >> 26118352

Patients perception of self-administrated medication in the treatment of hereditary angioedema.

Adrian Wang1, Andrew Fouche1, Timothy J Craig2.   

Abstract

BACKGROUND: Early therapy of hereditary angioedema (HAE) decreases morbidity, improves outcomes, decreases absenteeism, and possibly decreases mortality. This can be accomplished best with self-therapy. Previously, the authors examined barriers to self-therapy from the perspective of the nurse and the physician, but data are lacking on what patients perceive as major barriers to self-administered therapy for HAE.
OBJECTIVE: To identify those barriers in a prospective fashion by patient interview.
METHODS: After approval from the institutional review board, a telephone survey was performed of patients with HAE from a database of patients who were recently seen in the clinic. The survey focused on anxiety, depression, stress, concerns regarding method of administration, the ability to inject themselves, and what they perceived as barriers to providing self-care.
RESULTS: Ninety-two patients were contacted and 59 agreed to participate. With 69% of those patients currently undergoing self-administered treatment, the results showed minimal depression and anxiety, a high satisfaction with treatment, and significant compliance with treatment. Most of those not yet on self-administered therapy wanted to start despite being satisfied with the care received in the emergency department. They also believed care at home would be optimal. The main concern of the 2 groups was not being able to treat themselves in the event of an HAE attack.
CONCLUSION: From these data, it is obvious that most patients are willing to self-treat. This suggests that physicians should encourage self-treatment of HAE to improve outcomes and quality of life of patients with HAE.
Copyright © 2015 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26118352     DOI: 10.1016/j.anai.2015.06.006

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  10 in total

1.  The usage, quality and relevance of information and communications technologies in patients with chronic urticaria: A UCARE study.

Authors:  Marcus Maurer; Karsten Weller; Markus Magerl; Rasmus Robin Maurer; Emanuel Vanegas; Miguel Felix; Annia Cherrez; Valeria L Mata; Alicja Kasperska-Zajac; Agnieszka Sikora; Daria Fomina; Elena Kovalkova; Kiran Godse; Nimmagadda Dheeraj Rao; Maryam Khoshkhui; Sahar Rastgoo; Roberta Fachini Jardim Criado; Mohamed Abuzakouk; Deepa Grandon; Martijn van Doorn; Solange Olliveira Rodrigues Valle; Eduardo Magalhães de Souza Lima; Simon Francis Thomsen; German D Ramón; Edgar E Matos Benavides; Andrea Bauer; Ana Maria Giménez-Arnau; Emek Kocatürk; Carole Guillet; Jose Ignacio Larco; Zuo-Tao Zhao; Michael Makris; Carla Ritchie; Paraskevi Xepapadaki; Luis Felipe Ensina; Sofia Cherrez; Ivan Cherrez-Ojeda
Journal:  World Allergy Organ J       Date:  2020-10-30       Impact factor: 4.084

2.  An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension.

Authors:  Marc A Riedl; Jonathan A Bernstein; Timothy Craig; Aleena Banerji; Markus Magerl; Marco Cicardi; Hilary J Longhurst; Mustafa M Shennak; William H Yang; Jennifer Schranz; Jovanna Baptista; Paula J Busse
Journal:  Clin Transl Allergy       Date:  2017-10-06       Impact factor: 5.871

3.  Suffocation due to Acute Airway Edema in a Patient with Hereditary Angioedema Highlighted the Need for Urgent Improvements in Treatment Availability in Japan.

Authors:  Daisuke Honda; Isao Ohsawa; Yuki Shimizu; Masayuki Maiguma; Teruo Hidaka; Hitoshi Suzuki; Hiroaki Io; Satoshi Mano; Hisatsugu Takahara; Hisaki Rinno; Yasuhiko Tomino; Yusuke Suzuki
Journal:  Intern Med       Date:  2018-04-27       Impact factor: 1.271

4.  Treatment patterns and healthcare resource utilization among patients with hereditary angioedema in the United States.

Authors:  Marc A Riedl; Aleena Banerji; Michael E Manning; Earl Burrell; Namita Joshi; Dipen Patel; Thomas Machnig; Ming-Hui Tai; Douglas J Watson
Journal:  Orphanet J Rare Dis       Date:  2018-10-12       Impact factor: 4.123

5.  Hereditary angioedema patients would prefer newer-generation oral prophylaxis.

Authors:  Daniela Geba; Johan Mohd Sani; Michaela Gascon; Rebecca Hahn; Kavita Aggarwal; Jinky Rosselli
Journal:  J Drug Assess       Date:  2021-01-06

6.  Indirect Comparison of Lanadelumab and Intravenous C1-INH Using Data from the HELP and CHANGE Studies: Bayesian and Frequentist Analyses.

Authors:  Joan Mendivil; Mia Malmenäs; Katrin Haeussler; Matthias Hunger; Gagan Jain; Giovanna Devercelli
Journal:  Drugs R D       Date:  2021-03-01

Review 7.  Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report.

Authors:  Konrad Bork; John T Anderson; Teresa Caballero; Timothy Craig; Douglas T Johnston; H Henry Li; Hilary J Longhurst; Cristine Radojicic; Marc A Riedl
Journal:  Allergy Asthma Clin Immunol       Date:  2021-04-19       Impact factor: 3.406

8.  High attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational study.

Authors:  Veronica Squeglia; Alessandro Barbarino; Maria Bova; Carmela Gravante; Angelica Petraroli; Giuseppe Spadaro; Massimo Triggiani; Arturo Genovese; Gianni Marone
Journal:  Orphanet J Rare Dis       Date:  2016-09-29       Impact factor: 4.123

9.  Use of a C1 Inhibitor Concentrate in Adults ≥65 Years of Age with Hereditary Angioedema: Findings from the International Berinert® (C1-INH) Registry.

Authors:  Anette Bygum; Inmaculada Martinez-Saguer; Murat Bas; Jeffrey Rosch; Jonathan Edelman; Mikhail Rojavin; Debora Williams-Herman
Journal:  Drugs Aging       Date:  2016-11       Impact factor: 3.923

10.  International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency.

Authors:  H Farkas; I Martinez-Saguer; K Bork; T Bowen; T Craig; M Frank; A E Germenis; A S Grumach; A Luczay; L Varga; A Zanichelli
Journal:  Allergy       Date:  2016-09-08       Impact factor: 13.146

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.